Skip to main content

Duke to Start Trial of Promising COVID Antibody Treatment

If treatment is effective, it would advance COVID care until vaccine is developed

The Duke Human Vaccine Institute (DHVI) has been given approval to launch a Phase 1 clinical trial of one of its most promising antibody treatments for COVID-19. This would be a temporary treatment until a vaccine is developed. The DHVI also is developing a pan-coronavirus vaccine that would combat future iterations of COVID-19 and similar viruses, and also researching if saliva can be used as an accurate indicator of COVID-19 infection.